These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

82 related items for PubMed ID: 9097851

  • 1. [Enzyme determination in vitro of inhibitor activity of beta-lactamase from tazobactam. Comparison with high performance liquid chromatography].
    Sotto A, Brunschwig C, Ramuz M, Jourdan J.
    Pathol Biol (Paris); 1997 Jan; 45(1):77-81. PubMed ID: 9097851
    [Abstract] [Full Text] [Related]

  • 2. High-performance liquid chromatographic determination of tazobactam by precolumn derivatization.
    Peyrin E, Guillaume Y, Guinchard C.
    J Chromatogr B Biomed Appl; 1995 Oct 06; 672(1):160-4. PubMed ID: 8590930
    [Abstract] [Full Text] [Related]

  • 3. Exploring the effectiveness of tazobactam against ceftazidime resistant Escherichia coli: insights from the comparison between susceptibility testing and beta-lactamase inhibition.
    Bethel CR, Hujer AM, Helfand MS, Bonomo RA.
    FEMS Microbiol Lett; 2004 May 01; 234(1):99-103. PubMed ID: 15109726
    [Abstract] [Full Text] [Related]

  • 4. Rapid determination of sulbactam and tazobactam in human serum by high-performance liquid chromatography.
    Guillaume Y, Peyrin E, Guinchard C.
    J Chromatogr B Biomed Appl; 1995 Mar 24; 665(2):363-71. PubMed ID: 7795816
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Mechanism of inhibition of the class A beta -lactamases PC1 and TEM-1 by tazobactam. Observation of reaction products by electrospray ionization mass spectrometry.
    Yang Y, Janota K, Tabei K, Huang N, Siegel MM, Lin YI, Rasmussen BA, Shlaes DM.
    J Biol Chem; 2000 Sep 01; 275(35):26674-82. PubMed ID: 10837472
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model.
    Nicasio AM, VanScoy BD, Mendes RE, Castanheira M, Bulik CC, Okusanya OO, Bhavnani SM, Forrest A, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG.
    Antimicrob Agents Chemother; 2016 Apr 01; 60(4):2075-80. PubMed ID: 26787689
    [Abstract] [Full Text] [Related]

  • 9. Tazobactam inactivation of SHV-1 and the inhibitor-resistant Ser130 -->Gly SHV-1 beta-lactamase: insights into the mechanism of inhibition.
    Pagan-Rodriguez D, Zhou X, Simmons R, Bethel CR, Hujer AM, Helfand MS, Jin Z, Guo B, Anderson VE, Ng LM, Bonomo RA.
    J Biol Chem; 2004 May 07; 279(19):19494-501. PubMed ID: 14757767
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Determination of 6-beta-bromopenicillanic acid (brobactam) in human serum by high-performance liquid chromatography (HPLC) using solid phase extraction for sample preparation.
    Woodcock JM, Wolstenholme MR, Andrews JM, Wise R.
    J Antimicrob Chemother; 1994 Jan 07; 33(1):157-61. PubMed ID: 8157556
    [No Abstract] [Full Text] [Related]

  • 12. In vitro pharmacodynamic evaluation of ceftolozane/tazobactam against β-lactamase-producing Escherichia coli in a hollow-fibre infection model.
    Soon RL, Lenhard JR, Bulman ZP, Holden PN, Kelchlin P, Steenbergen JN, Friedrich LV, Forrest A, Tsuji BT.
    Int J Antimicrob Agents; 2017 Jan 07; 49(1):25-30. PubMed ID: 27931793
    [Abstract] [Full Text] [Related]

  • 13. Inactivation of CMY-2 beta-lactamase by tazobactam: initial mass spectroscopic characterization.
    Bonomo RA, Liu J, Chen Y, Ng L, Hujer AM, Anderson VE.
    Biochim Biophys Acta; 2001 Jun 11; 1547(2):196-205. PubMed ID: 11410275
    [Abstract] [Full Text] [Related]

  • 14. Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam-β-Lactamase Inhibitor Combinations.
    Soon RL, Lenhard JR, Bulman ZP, Holden PN, Kelchlin P, Steenbergen JN, Friedrich LV, Forrest A, Tsuji BT.
    Antimicrob Agents Chemother; 2016 Apr 11; 60(4):1967-73. PubMed ID: 26729494
    [Abstract] [Full Text] [Related]

  • 15. Interaction of tazobactam with Staphylococcus aureus PC1 beta-lactamase: a molecular modelling and enzyme kinetics study.
    Denny BJ, Toomer CA, Lambert PA.
    Microbios; 1994 Apr 11; 78(317):245-57. PubMed ID: 8078414
    [Abstract] [Full Text] [Related]

  • 16. [In vitro antibacterial activity of piperacillin-tazobactam in combination with netilmicin or amikacin against Enterobacteriaceae resistant to amoxicillin].
    Duez JM, Siebor E, Pechinot A, Cordin X, Chamard-Neuwirth C, Kazmierczak A.
    Pathol Biol (Paris); 1995 Mar 11; 43(3):208-14. PubMed ID: 7675548
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Allyl and propargyl substituted penam sulfones as versatile intermediates toward the syntheses of new beta-lactamase inhibitors.
    Sandanayaka VP, Feigelson GB, Prashad AS, Yang Y, Petersen PJ.
    Bioorg Med Chem Lett; 2001 Apr 23; 11(8):997-1000. PubMed ID: 11327608
    [Abstract] [Full Text] [Related]

  • 20. [Beta-lactamase inhibitor: tazobactam].
    Zhang YL, Li JT.
    Sheng Li Ke Xue Jin Zhan; 1997 Oct 23; 28(4):370-3. PubMed ID: 11038697
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.